Sign up
Pharma Capital

Zynerba Pharmaceuticals shares sink after unsuccessful trial of cannabis-based skin patch

The company will shift its focus to ZYN002, a treatment for epilepsy
ZYN001 delivers THC through a transdermal patch

Zynerba Pharmaceuticals Inc (NASADAQ:ZYNE) shares sank following an unsuccessful early-stage trial of ZYN001, its cannabinoid skin patch.

ZYN001 is designed to deliver THC through a transdermal patch.

In the placebo-controlled Phase 1 study, a total of 60 volunteers participated in the study with differently formulated patches and varying wear times.

While there were no serious adverse effects detected, the skin patch did not achieve its goal of target THC levels in the blood.

The company, which develops cannabis-based therapies for rare neuropsychiatric disorders, will shift its focus to ZYN002 Fragile X syndrome, a treatment for epilepsy.

Shares of the Pennsylvania-based company fell more than 20% to US$7.64 in Thursday pre-market trading.

View full ZYNE profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.